clinical trial · NCT05962151
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Refractory Chronic CoughNAL ERPlacebo
brief summary
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
started
Nov 30, 2023
primary completion
Jan 6, 2025
completion
Jan 6, 2025
last updated
Mar 30, 2026
official title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol